Zymeworks soared 34% after its partnered drug Ziihera posted strong Phase 3 data, with Jazz Pharmaceuticals showing it improved outcomes in a tough cancer — a breakthrough moment for the ...
Pacira jumped into M&A chatter after investor DOMA Perpetual urged a full sale, arguing the biotech could fetch $66/share. Activist pressure follows solid EXPAREL growth but weak stock performance. ...
Nektar Therapeutics rises after reports of Eli Lilly’s buyout interest and strong Phase IIb results for REZPEG. With FDA Fast Track status and solid cash reserves, investor optimism builds. ...